Mikael Kubista1,2, Robert Sjöback1, Marie Jindrichova2, Eva Rohlova1, Vendula Novosadová1,2, Siegfrid Hauch3, Katarina Kolostova4, Bahriye Aktas5, Mitra Tewes5, Maren Bredemeier5, Sabine Kasimir-Bauer5
1TATAA Biocenter, Sweden;
2Institute of Biotechnology, CAS, Czech Republic;
5University Hospital Essen
We have developed a strategy to predict response to treatment of cancer patients based on expression profiling of circulating tumour cells (CTCs). CTCs are collected from blood using AdnaGen immunomagnetic capture followed by expression profiling with TATAA Biocenter GrandPerformance assays via preamplification. Preliminary results from a pilot study on breast cancer (BC) patients demonstrates excellent sensitivity, technical reproducibility and identifies a set of genes that separates a group of non-responders. The approach shows great promise as liquid biopsy for the motoring of treatments and prediction of responses.
|Back to Microgenomics & Single-Cell Diagnostics|